Individual differences exist in sensitivity to the psychotomimetic effect of cannabis; the molecular genetic basis underlying differential sensitivity remains elusive.
To investigate whether selected schizophrenia candidate single-nucleotide polymorphisms (SNPs) moderate effects of cannabis use.
Interactions between recent cannabis use, determined by urinalysis results, and 152 SNPs in 42 candidate genes were examined in 740 unaffected siblings of 801 patients with psychosis to examine genetic moderation of the association between Structured Interview for Schizotypy–Revised positive schizotypy and recent cannabis use (at-risk paradigm). The SNPs showing Bonferroni-adjusted association in the at-risk paradigm were used in a case-only analysis in the 801 patients, as well as in a case-sibling and case-control analysis (using 419 controls) focusing on genetic moderation of developmental effects of cannabis on later psychotic disorder.
The Netherlands and Flanders, Belgium.
Eight hundred one patients with psychosis and their 740 unaffected siblings.
Significant interaction between any of the selected SNPs and cannabis in the at-risk paradigm, followed by selective case-only, case-sibling, and case-control analyses.
In the unaffected siblings, 16 SNPs in 12 genes showed significant interaction at P < .05, 3 of which survived correction for multiple testing (P < .0003), situated in AKT1 (rs2494732 and rs1130233) and LRRTM1 (rs673871). Follow-up analysis supported AKT1 rs2494732 × cannabis interaction in the case-only (β = 0.20; P = .007), case-sibling (interaction P = .040), and case-control (interaction P = .057) analyses, with individuals with C/C genotypes having an approximately 2-fold odds of being diagnosed with a psychotic disorder when having used cannabis. In the unaffected siblings, the AKT1 × cannabis interaction explained 2.2% additional variance in schizotypy in the whole sample and 19.0% additional variance in the exposed siblings with recent cannabis use.
Genetic variation in AKT1 may mediate both short-term as well as longer-term effects on psychosis expression associated with use of cannabis, possibly through a mechanism of cannabinoid-regulated AKT1/GSK-3 signaling downstream of the dopamine D2 receptor.
This genome-wide association analysis identifies a novel locus for neuroticism and shows polygenic association with major depressive disorder (MDD).
This cross-sectional study demonstrates that psychiatric comorbidities are common among individuals with Tourette syndrome and that most comorbidities begin early in life.
This multicenter collaborative study explores whether biologically defined groups of genes are enriched in episodic memory performance across age, memory encoding–related brain activity, and Alzheimer disease.
Blasi et al examine the functional effects of the serotonin receptor 2a (5-HT2AR) gene on 5-HT2AR
messenger RNA and protein expression, on prefrontal phenotypes linked with genetic risk for
schizophrenia, and on treatment with olanzapine.
This genome-wide association study assesses analyses from 3 studies of substance use disorder genetics to identify DSM-IV criteria for cannabis dependence in a large African American and European American cohort.
This study examines the role of microRNAs in the context of genetic variation associated with schizophrenia.
Fears et al aim to identify quantitative neurocognitive, temperament-related, and neuroanatomical phenotypes that appear heritable and associated with severe bipolar disorder (BP) (bipolar I disorder) and therefore suitable for genetic linkage and association studies aimed at identifying variants contributing to bipolar I disorder risk.